AstraZeneca’s triple-hit COPD inhaler meets goals in phase 3 by Nick Paul Taylor Friday, January 26, 2018 The trial’s success against eight out of nine lung function endpoints positions AstraZeneca to start filing for approval in the second half of 2018.
